Q2 2021 EPS Estimates for OPKO Health, Inc. Reduced by Barrington Research (NASDAQ:OPK)

Share on StockTwits

OPKO Health, Inc. (NASDAQ:OPK) – Equities research analysts at Barrington Research cut their Q2 2021 earnings per share estimates for shares of OPKO Health in a report released on Thursday, April 29th. Barrington Research analyst M. Petusky now anticipates that the biotechnology company will earn $0.02 per share for the quarter, down from their prior forecast of $0.04. Barrington Research has a “Outperform” rating and a $8.00 price target on the stock. Barrington Research also issued estimates for OPKO Health’s Q3 2021 earnings at $0.02 EPS, FY2021 earnings at $0.23 EPS, Q2 2022 earnings at $0.05 EPS, Q4 2022 earnings at $0.05 EPS and FY2022 earnings at $0.18 EPS.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings results on Wednesday, April 28th. The biotechnology company reported $0.05 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.05. OPKO Health had a negative return on equity of 2.61% and a negative net margin of 9.79%.

OPK stock opened at $3.96 on Monday. The stock has a market capitalization of $2.65 billion, a PE ratio of -22.00, a price-to-earnings-growth ratio of 5.84 and a beta of 1.98. The company’s 50-day moving average is $4.37 and its 200-day moving average is $4.44. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.27 and a quick ratio of 0.94. OPKO Health has a 1 year low of $1.91 and a 1 year high of $6.47.

In related news, CEO Phillip Md Et Al Frost acquired 300,000 shares of the business’s stock in a transaction dated Friday, March 5th. The shares were bought at an average price of $3.91 per share, with a total value of $1,173,000.00. Following the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $11,999,598.41. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 40.90% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in OPK. Norges Bank bought a new position in OPKO Health in the 4th quarter valued at about $17,328,000. BlackRock Inc. lifted its position in OPKO Health by 3.5% in the 4th quarter. BlackRock Inc. now owns 37,628,639 shares of the biotechnology company’s stock valued at $148,632,000 after acquiring an additional 1,285,944 shares in the last quarter. Nordea Investment Management AB bought a new position in OPKO Health in the 4th quarter valued at about $5,015,000. First Trust Advisors LP bought a new position in OPKO Health in the 4th quarter valued at about $4,633,000. Finally, Renaissance Technologies LLC bought a new position in shares of OPKO Health during the 4th quarter worth approximately $2,348,000. 28.51% of the stock is currently owned by institutional investors and hedge funds.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services.

Featured Article: Back-End Load

Earnings History and Estimates for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.